346 results on '"Potluri R"'
Search Results
2. RWD157 Assessment of Real-World Treatment Patterns and Healthcare Resource Utilization (HCRU) in Patients with Lenalidomide-Refractory Relapsed/Refractory Multiple Myeloma (RRMM) from the US Optum Database
3. EE86 Healthcare Resource Utilization (HCRU) and Associated Costs Among Patients with Acute Myeloid Leukemia (AML) Treated with Oral Azacitidine as Maintenance and Those Eligible but Not Treated Using a US Claims Database
4. EE660 Real-World Economic Burden and Healthcare Resource Utilization (HCRU) Among Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) in the United States
5. EE620 Increase in HCM-Related Economic Burden Due to Atrial Fibrillation in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: A Claims Analysis of 9490 Patients
6. P46 SEER-MEDICARE DATABASE: REAL-WORLD TREATMENTS AND OUTCOMES IN PATIENTS WITH LENALIDOMIDE-REFRACTORY RELAPSED MULTIPLE MYELOMA TREATED WITH 1–3 PRIOR LINES OF THERAPY, INCLUDING A PI AND IMID
7. Impact of cardiovascular risk factors and disease on length of stay and mortality in patients with acute coronary syndromes
8. EE491 Real-World Costs, Health Care Resource Utilization (HCRU), and Outcomes Among Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) in the US
9. EE246 Real-World Costs and Health Care Resource Utilization (HCRU) Among Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) in the US
10. EP08.02-016 Frontline and Post-Osimertinib Therapy for EGFR-mutant Advanced NSCLC: Treatment Patterns, Outcomes, Healthcare Use and Costs
11. Low-Cost Undergraduate Control Systems Experiments Using Microcontroller-Based Control of a DC Motor
12. EE278 Economic Burden of Acute Myeloid Leukemia Relapse in US Patients
13. P899: REAL-WORLD ASSESSMENT OF TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH LENALIDOMIDE-REFRACTORY RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE OPTUM DATABASE
14. P570: REAL-WORLD EFFICACY OUTCOMES OF VENETOCLAX PLUS AZACITIDINE VS INTENSIVE CHEMOTHERAPY FOR INDUCTION THERAPY IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA
15. Alzheimer's disease and co-morbidity: Increased prevalence and possible risk factors of excess mortality in a naturalistic 7-year follow-up
16. EE186 Trends in Cost of Treatment with Immuno-oncology Drugs in the US
17. Type-2 diabetes mellitus in schizophrenia: Increased prevalence and major risk factor of excess mortality in a naturalistic 7-year follow-up
18. POSC108 Estimated Hospitalization-Related Costs with Oral Azacitidine (ORAL-AZA) vs. Placebo for Remission Maintenance in Patients with Acute Myeloid Leukemia (AML) in Sweden and Norway
19. An Enhancing Diabetic Retinopathy Classification and Segmentation based on TaNet
20. Apolipoprotein E allele 4 is not a sufficient or a necessary predictor of the development of Mild Cognitive Impairment
21. Risk factors for mortality in Down syndrome
22. Club 35 Poster session 2: Thursday 4 December 2014, 08: 30–18: 00Location: Poster area
23. PRO78 Real-World Treatment Patterns in Patients with Light Chain (AL) Amyloidosis: Analysis of the Optum US Electronic Health Records (EHR) and Commercial Claims Database
24. PRO21 Burden of Illness in Patients with Light Chain (AL) Amyloidosis: A Real World Study Using Optum Claims Database
25. Effect of ethnicity on live birth rates after in vitro fertilisation or intracytoplasmic sperm injection treatment: possible explanations and further observations
26. P740Hyperlipidaemia as a risk factor for breast cancer?
27. Secular trends in the cardiovascular risk profile and mortality of stroke admissions in an inner city, multiethnic population in the United Kingdom (1997–2005)
28. Poster session Wednesday 11 December all day display: 11/12/2013, 09: 30–16: 00Location: Poster area
29. PCN105 Comparison of Healthcare Costs in France of Combination Nivolumab and Ipilimumab Treatment Versus Nivolumab Monotherapy and Ipilimumab Monotherapy in Advanced Melanoma
30. PCV68 Increasing Burden of Cardiovascular Disease, the Associated Risk Factors and Drug Utilization Among the Patients with LUNG Disease in the US: A Study Based on Nhanes from 2005 to 2018
31. Pregnancy complications in hyperemesis-affected pregnancy: a large hospital database study: FC1.01
32. Length of hospital stay is shorter in black and ethnic minority patients with diabetes
33. PCV16 Increasing Burden of Cardiovascular Disease (CVD), the Associated Risk Factors and Drug Utilization Among Smokers in the US: A Study Based on Nhanes from 2005 to 2016
34. PRS23 THE LONG-TERM IMPACT OF BEDAQUILINE-CONTAINING REGIMENS ON COST BURDEN TO THE HEALTHCARE SYSTEM AND FAMILIES OF PATIENTS WITH DRUG-RESISTANT TUBERCULOSIS IN INDONESIA
35. PCV48 INCREASING BURDEN OF CVD, THE ASSOCIATED RISK FACTORS AND DRUG UTILIZATION IN THE US: A STUDY BASED ON NHANES FROM 2005 TO 2016
36. Increased 5-year mortality in the migrant South Asian stroke patients with diabetes mellitus in the United Kingdom: The West Birmingham Stroke Project
37. PD01.09 Incidence and Predictors Associated with the Development of Pneumonitis in Non-Small Cell Lung Cancer Patients
38. PIN48 THE LONG-TERM IMPACT OF BEDAQUILINE-CONTAINING REGIMENS ON COST BURDEN OF DRUG-RESISTANT TUBERCULOSIS IN INDIA
39. PD01.08 Incidence and Predictors Associated with the Development of Peripheral Neuropathy in Non-Small Cell Lung Cancer Patients
40. PMH69 RISING DEPENDENCE ON ANTI-DEPRESSANTS AMONG ADULTS IN US: A STUDY BASED ON NHANES FROM 2005 TO 2016
41. PCN454 A MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF ELOTUZUMAB/POMALIDOMIDE/DEXAMETHASONE (EPD) VERSUS PANOBINOSTAT/BORTEZOMIB/DEXAMETHASONE (PANO-VD) AND DARATUMUMAB MONOTHERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
42. P6381Cardiac arrest patients presenting to hospitals at weekends are not subject to the weekend effect: insights from ACALM big data, United Kingdom
43. PF643 CHARACTERIZATION OF FRONTLINE TREATMENT PATTERNS AND THE PROPORTION OF PATIENTS REACHING SUBSEQUENT LINES OF THERAPY IN TRANSPLANT ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
44. PCN254 AN INDIRECT COMPARISON OF ELOTUZUMAB, CARFILZOMIB, AND DARATUMUMAB WHEN GIVEN IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
45. PCN91 HEALTHCARE COST COMPARISON ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB VERSUS NIVOLUMAB MONOTHERAPY AND IPILIMUMAB MONOTHERAPY IN ADVANCED MELANOMA
46. PCN300 EVALUATION OF OVERALL SURVIVAL ASSOCIATED WITH CHANGE IN DOSING OF BORTEZOMIB, MELPHALAN, AND PREDNISONE REGIMEN IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: A REAL-WORLD STUDY
47. PMH38 INCREASING PREVALENCE OF DEPRESSION AND THE ASSOCIATED RISK FACTORS IN THE US: A STUDY BASED ON NHANES FROM 2005 TO 2016
48. Abstract P4-16-05: Avoidable acute care use associated with nausea and emesis among patients receiving AC, carboplatin, or cisplatin for breast cancer
49. P6049Regional differences in process of care and clinical outcome among patients with ST-elevation myocardial infarction in Canada and the United Kingdom
50. P6046Temporal trends of ST-elevation myocardial infarction incidence and 30-day mortality: a transatlantic comparison between Alberta, Canada and Northern England, United Kingdom
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.